CLINICAL_TRIALS ClinicalTrials.gov record update

Ph1 Cyclophosphamide & Alemtuzumab in CD52+ R/R Double-Hit, Diffuse Lg B-cell or High Gr B-cell Lymphomas, NOS With MYC & BCL2 Over-expression, MYC-Positive Transformed Follicular Lymphoma, & CD52+ Mature T-cell Lymphoproliferative Disorder

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03132584
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:02.412481+00:00
Published At: 2019-01-14T00:00:00+00:00
Record Updated At: 2019-01-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non Hodgkin Lymphoma", "High-grade B-cell Lymphoma", "Diffuse Large B Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-01-14"
protocolSection.identificationModule.nctId: "NCT03132584"
protocolSection.identificationModule.officialTitle: "Ph1 Cyclophosphamide \u0026 Alemtuzumab in CD52+ R/R Double-Hit, Diffuse Lg B-cell or High Gr B-cell Lymphomas, NOS With MYC \u0026 BCL2 Over-expression, MYC-Positive Transformed Follicular Lymphoma, \u0026 CD52+ Mature T-cell Lymphoproliferative Disorder"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.